Drug Trial Radar · NCT07833618
A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Jan 1, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Darwin Origin (Hubei) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ALT001 is an allogeneic unrelated human umbilical cord mesenchymal stem cell-derived protein complex under investigation for the treatment of amyotrophic lateral sclerosis (ALS). This is a multicenter, randomized, double-blind, placebo-controlled, Phase 2 dose-ranging study in patients with ALS. Approximately 150 participants will be randomized 1:1:1 to receive ALT001 1.0 μg/kg, ALT001 2.0 μg/kg, or matching placebo by intravenous infusion during the 24-week double-blind (DB) treatment period. During the OLE period, the active treatment groups will continue to receive their original dose under blinded conditions, whereas the placebo group will undergo re-randomization in a 1:1 ratio to receive 1.0 or 2.0 μg/kg ALT001. The primary objective is to evaluate the dose-response relationship and efficacy of ALT001 at 1.0 and 2.0 μg/kg and to determine the recommended dose for subsequent studies. Secondary objectives include assessment of biomarkers related to efficacy and exploration of changes in cytokines, immune function, proteomics, and immunogenicity (anti-drug antibodies, ADA), as well as evaluation of the safety of ALT001.
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
ALT001 1.0 μg/kgDrug
Allogeneic unrelated human umbilical cord mesenchymal stem cell-derived protein complex; 130 μg/vial (lyophilized powder); reconstituted and administered by intravenous infusion at 1.0 μg/kg body weight.
ALT001 2.0 μg/kgDrug
Allogeneic unrelated human umbilical cord mesenchymal stem cell-derived protein complex; 130 μg/vial (lyophilized powder); reconstituted and administered by intravenous infusion at 2.0 μg/kg body weight.
PlaceboDrug
Matching placebo (ALT001 simulant) containing no active ingredient; identical in appearance, packaging, labeling, and post-reconstitution infusion presentation to ALT001.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total scoreTime frame: Baseline to Week 24 (Week0, Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24 after randomization)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Capital Medical University Affiliated Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.